Juvenile Huntington's Disease (JHD), also called Huntington's disease with childhood onset, is a rare, rapidly progressive neurodegenerative disorder affecting individuals under 20 years of age. It accounts for approximately 1-5% of all Huntington's disease cases. JHD is caused by the same CAG trinucleotide repeat expansion in the HTT gene as adult-onset HD, but presents with distinct clinical features, more severe progression, and is more frequently inherited from the paternal allele.
The defining feature of JHD is an exceptionally long CAG repeat expansion, typically exceeding 60 repeats. The longer the repeat, the earlier the onset and the more likely the presentation will include parkinsonian features, cognitive decline, and seizures rather than the classic chorea seen in adult HD.
| Property |
Value |
| CAG Repeat Threshold |
>60 repeats (classic JHD definition); sometimes >55 in broader definitions |
| Parental Origin |
~80% paternal (vs ~50% in adult HD) |
| Anticipation |
Strong; longer repeats expand more during spermatogenesis |
| Inheritance |
Autosomal dominant |
| Chromosome |
4p16.3 (HTT gene) |
| Protein |
Huntingtin (3,142 amino acids) |
The mechanism of paternal predominance in JHD relates to germline CAG repeat instability during spermatogenesis. Longer CAG tracts are more prone to expansion when transmitted through sperm, explaining why JHD disproportionately inherits from fathers.
JHD motor presentation differs markedly from adult HD:
- Bradykinesia and rigidity: Hypokinetic-parkinsonian features dominate, especially with very long CAG repeats (>80)
- Dystonia: Prominent early involvement, often affecting axial musculature
- Chorea: May be absent or less prominent than in adults; when present, typically less severe
- Seizures: Present in 30-50% of JHD cases (rare in adult HD), particularly with early onset
- Myoclonus: Observed in some patients
- Ataxia: Cerebellar signs can emerge as disease progresses
- Rapid cognitive decline: More accelerated than in adult HD
- Developmental regression: Loss of previously acquired milestones
- Learning difficulties: Problems with working memory, executive function, attention
- Behavioral changes: Irritability, aggression, ADHD-like symptoms, mood lability
- Regression in language: Progressive deterioration of verbal skills
- Depression: Common and often severe
- Anxiety: Significant anxiety and panic symptoms
- Obsessive-compulsive behaviors: May emerge
- Psychosis: Less common but can occur
- Apathy: Progressive loss of motivation and interest
JHD progresses significantly faster than adult-onset HD:
- Mean survival: 10-15 years from symptom onset (vs 15-20 years in adults)
- More rapid functional decline: Earlier loss of ambulation, communication, and self-care
- Stage progression: May pass through stages more rapidly
- Cause of death: Pneumonia, choking, respiratory failure, injuries from falls
Genetic testing confirms the diagnosis:
- CAG repeat count: ≥60 confirms HD; repeat length correlates with age of onset
- Predictive testing: Available for at-risk individuals (minors at 50% risk)
- Prenatal testing: Possible for families who wish to know
- Neurological examination: Motor, cognitive, behavioral evaluation
- Neuroimaging (MRI): Striatal atrophy (caudate and putamen), cortical atrophy, white matter changes
- Developmental assessment: For children presenting with developmental regression
- Electroencephalogram (EEG): For patients with seizures
JHD can be confused with other childhood-onset neurological disorders:
- Parkinsonism: Young-onset PD, dystonia syndromes, Wilson disease
- Seizure disorders: Childhood epilepsy syndromes
- Neurodegeneration: Metachromatic leukodystrophy, mitochondrial disorders
- Behavioral/psychiatric: Severe ADHD, autism spectrum disorder with regression
| Symptom |
Treatment |
Notes |
| Chorea/Dystonia |
Tetrabenazine, deutetrabenazine |
May help if chorea prominent |
| Seizures |
Levetiracetam, valproate, clonazepam |
Standard antiepileptics |
| Behavioral |
SSRIs, atypical antipsychotics |
Non-pharmacological first |
| Depression |
SSRIs, psychotherapy |
Monitor suicidality |
| Parkinsonism |
Levodopa (variable response) |
May help rigidity/bradykinesia |
| Myoclonus |
Clonazepam, levetiracetam |
Often refractory |
- Physical therapy: Maintain mobility, prevent contractures, manage dystonia
- Occupational therapy: Preserve activities of daily living
- Speech therapy: Communication support, swallowing assessment
- Nutritional support: Prevent weight loss, manage dysphagia
- Educational support: Individualized education plans (IEPs), special education services
- Psychological support: For patient and family
The longer CAG repeats in JHD produce more severe mutant huntingtin protein toxicity through:
- Gain-of-function toxicity: Mutant huntingtin protein aggregates, disrupts transcription, impairs autophagy, and damages mitochondria
- Striatal vulnerability: Medium spiny neurons in the caudate and putamen are most affected
- Accelerated neurodegeneration: Longer repeats correlate with faster cell death rates
- Developmental effects: The mutant protein may interfere with normal brain development, contributing to earlier symptoms
- Somatic CAG expansion: Understanding repeat instability in peripheral tissues as a biomarker
- Gene-silencing therapies: ASOs and RNAi approaches targeting HTT mRNA (e.g., tominersen, others)
- Huntingtin-lowering trials: Ongoing work in both adult and juvenile HD
- Biomarker development: Neurofilament light chain (NfL), mutant huntingtin in CSF